Soley Therapeutics, Inc.

Soley Therapeutics, Inc. , based in the US, specializes in biology-first drug discovery, utilizing human cells as sensors to innovate first-in-class medicines, enhancing drug safety and efficacy through advanced imaging and AI technologies. Founded in 2020 and headquartered in South San Francisco, USA, Soley Therapeutics focuses on pioneering approaches in drug discovery. The company has raised USD 200.

00 mn in its Series C funding round on January 7, 2026, led by Surveyor Capital. Soley has engaged in one deal to date, and the latest funding supports its efforts to develop a solid tumor candidate and advance its AML drug program into clinical trials. Soley Therapeutics specializes in biology-first drug discovery, leveraging human cells as advanced sensors to develop first-in-class medicines. The company's core offerings integrate proprietary imaging, artificial intelligence (AI), and automation technologies to analyze cellular responses to stress and drug exposure, facilitating the rapid translation of cellular data into therapeutic solutions.

Soley targets unmet medical needs in areas such as oncology and regenerative medicine, serving pharmaceutical companies and research institutions across North America, Europe, and Asia. Soley Therapeutics generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions. The company's business model includes business-to-business (B2B) transactions, providing tailored solutions that leverage its innovative drug discovery platform. Revenue is structured around milestone payments and licensing agreements for proprietary technologies and drug candidates, facilitating ongoing research and development while promoting commercialization efforts.

Soley Therapeutics plans to utilize the USD 200. 00 mn raised in Series C funding to advance its AML drug program into clinical trials and progress a solid tumor candidate to IND-enabling studies. The company is also focused on scaling its AI-driven discovery platform to enhance its drug development capabilities. Upcoming efforts include launching new products aimed at addressing unmet medical needs in oncology and expanding its market reach into Europe and Asia by 2027.